Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mindfulness may boost medication adherence in liver transplant patients

NCT ID NCT06879106

Disease control Sponsor: Bitlis Eren University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a type of talk therapy called Mindfulness-Based Cognitive Therapy (MBCT) can help people who have had a liver transplant stick to their anti-rejection medication schedule and feel more motivated. 140 adult liver transplant recipients took part. The goal was to see if MBCT improves how well patients follow their lifelong drug plan, which is critical for keeping their new organ healthy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

140 people

The number who actually took part.

Started

Feb 2025

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Applying to the outpatient clinic for routine follow-up after liver transplantation, * Receiving immunosuppressive treatment for at least one month after liver transplantation, * Being 18 years old or older, * Not having a communication barrier, * Agreeing to participate in the study. Exclusion Criteria: * Having any hearing or mental problems * Wanting to leave the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Compliance, treatment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Patient Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Compliance, treatment Immunosuppression Liver transplant; complications

Contacts and locations

Locations

  • Bitlis Eren University

    Bitlis, 13100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.